LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate
FB825 is a first-in-class drug candidate with a unique mechanism of action (MoA) targeting the CεmX domain of the membrane bound IgE (mIgE) causing a depletion of mIgE positive B-cells. This new MoA holds promise as a treatment for atopic dermatitis and is expected to reduce the disease burden by lowering relevant inflammatory mediators as well as IgE levels.
“Having seen the first-in-human data of FB825 and the reduction in Eczema Area and
Severity Index scores (an indicator of AD severity), we feel that we are welcoming a
promising novel drug candidate into our development pipeline,” said Dr Kim Kjoeller,
Executive Vice President, Global Research & Development, LEO Pharma. “No two
patients are alike, and as there is a high unmet need we are committed to building a
diverse pipeline that represents a broad range of molecules and mechanisms of action”.
LEO Pharma and both Oneness Biotech and Microbio Shanghai see great potential in
FB825. If the anticipated treatment profile can be confirmed in the upcoming trials, the
product can be expected to help a significant number of patients suffering from atopic
diseases.
Under the terms of the agreement, LEO Pharma will make an upfront payment of
USD 40 million and offer milestone payments up to USD 530 million, followed by a tiered
high single-digit to double-digit royalties. Under the agreement, Oneness will be
responsible for executing the Phase 2a study for Atopic Dermatitis in the United States
and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China. LEO
Pharma will assume all the development responsibilities after the Phase 2a studies.
#END#
NOTES TO EDITORS
About FB825
FB825 is a humanized monoclonal antibody that binds to the CεmX domain of membrane
form IgE, leading to depletion of IgE+ B lymphocytes by inducing apoptosis and antibodydependent cellular cytotoxicity (ADCC). FB825 is scheduled to be tested in Phase 2 trials for Atopic Dermatitis in US and for Allergic Asthma in China. In addition, FB825 is granted an orphan drug designation by US FDA in Hyper IgE Syndrom (HIES).
About Atopic Dermatitis Atopic dermatitis (AD) – also known as ‘atopic eczema’ – is a chronic, inflammatory, heterogeneous skin disease characterized by intense itch and eczematous lesions.(2) AD is the most common inflammatory skin disease in the developed world,(3) affecting up to 5% of adults across the US, Canada, Europe and Japan.(4, 5)
About Asthma
Allergic Asthma, which is the most common form of asthma triggered by inhaling
allergens. The severe form of asthma affecting an estimated 300 million(1)
individuals worldwide, is a debilitating, potentially fatal disease that has a significant negative impact on patients’ lives, often leading to frequent, severe attacks, reduced lung function and a poor quality of life.
About Oneness Biotech
Oneness Biotech, a listed biotech company in Taiwan (TPEx: 4743), is dedicated to fulfilling the unmet needs in diabetes-related and immune diseases. Besides FB825, Oneness Biotech has another new drug, ON101 in diabetic foot ulcer that completed recruitment of its first global Phase 3 trial. According to its interim analysis, ON101 has achieved over 60% complete healing rate within 16 weeks (p=0.0065). In the past 20 years, all Phase 3 clinical trials in DFU have failed. In addition, Oneness Biotech’s pipeline further includes fully-human antibody anti-IL 6, anti-IL 33 and other new drugs under development. For more information, please visit: www.onenessbio.com.tw/en
About Microbio Shanghai
Microbio Shanghai (“MBS”) is a company focused on immune and metabolic diseases. MBS will conduct Phase 2 trial of FB825 in allergic asthma in China. In addition, MBS is specialized in research and development into nucleic acid medicines and microbiome via its unique microbial pharmaceutical technology platforms. Its library with hundreds of unique anaerobic commensal bacteria metabolites has obtained significant findings in treatment of diabetes and immune diseases which takes it a further step into nextgeneration medicines.
References
1. Msaoli et. al., Allergy 2004.
2. Weidinger S & Novak N. Atopic dermatitis. Lancet 2016;387:1109-1122.
3. Weidinger S et al. Atopic Dermatitis. Nat Rev Dis Primers 2018; 4(1):1.
4. Barbarot S, Auziere S et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi: 10.1111/all.13401.
5. Barbarot S et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018;73:1284-1293.
Contacts
LEO Pharma A/S
Maia Fredtoft Søchting,
Corporate Communications Manager
+45 2681 4579
mfddk@leo-pharma.com
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse
Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1
LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 202515.9.2025 15:00:00 CEST | Pressemeddelelse
For the second year in a row, LEO Pharma delivers its largest and most ambitious scientific programme ever at the 2025 European Academy of Dermatology and Venereology (EADV), setting a new standard by presenting an unprecedented volume of scientific content for the company, with 5 late-breaking presentations and 24 regular abstracts.1-29 LEO Pharma’s scientific programme at EADV 2025 spans multiple dermatological indications, mirroring the company’s strong commitment to addressing both the most prevalent chronic skin diseases and hard-to-treat conditions.1-29 Highlights from EADV 2025 includes exciting phase 3 data in biologic injectables as well as foam and cream formulations, illustrating the breadth of therapeutic approaches represented in LEO Pharma’s medical dermatology portfolio.1-29
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth18.8.2025 12:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2025 - In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted EBITDA margin in 2025 towards the upper-end of previously communicated expectations. In July, the FDA approval of Anzupgo® and partnership with Boehringer Ingelheim for SPEVIGO®, marked major strategic milestones demonstrating LEO Pharma’s commitment to advancing innovation in dermatology. Highlights LEO Pharma’s revenue increased by 6% year-on-year to DKK 6,789 million, and by 7% at constant exchange rates (CER) entirely driven by organic growth. The revenue growth was led by North America (+28% at CER), with Europe (+1% at CER) and Rest of World (+4% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 51% (CER). Sales
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:30:00 CEST | Pressemeddelelse
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs.
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)14.7.2025 13:00:00 CEST | Pressemeddelelse
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom